Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
polyvalent antigen-KLH conjugate vaccine + OPT-821
- Development stage
- Phase 1
- Lead developer
- Memorial Sloan Kettering Cancer Center
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
A therapeutic cancer vaccine regimen composed of a **polyvalent tumor-associated carbohydrate antigen (TACA) vaccine conjugated to keyhole limpet hemocyanin (KLH)** administered together with the **saponin-based immunologic adjuvant OPT-821**. The polyvalent vaccine includes antigens such as Globo H, GM2, Tn-MUC1, TF, and sTn linked to KLH to enhance immunogenicity, aiming to elicit anti-glycan and anti-MUC1 antibody responses against residual ovarian and related epithelial cancers. Clinical testing in ovarian cancer patients in second/third complete remission showed the combination was modestly immunogenic but did not improve progression-free or overall survival compared with OPT-821 alone. Developers and manufacturers are not explicitly named in the cited records; OPT-821 is described as a Quillaja saponaria–derived saponin adjuvant related to QS-21. The regimen has been investigated alone and in combination with bevacizumab in clinical studies.
- Other names
- polyvalent vaccine-KLH conjugate + OPT-821polyvalent antigen-KLH conjugate + OPT-821
02
Targets
Globo-HTn-MUC1 (Mucin-1 carrying Tn antigen)STn-MUC1 (Sialyl-Tn-MUC1)TF antigen (Thomsen-Friedenreich antigen)GM2 (Ganglioside GM2)
Beyond the preview
Go deeper on polyvalent antigen-KLH conjugate vaccine + OPT-821.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on polyvalent antigen-KLH conjugate vaccine + OPT-821.